Sigma-Aldrich Introduces Methylated DNA Quantification Technology for Epigeneti...(t focuses on developing and providing in...)

Date:10/29/2008

t focuses on developing and providing innovative technology and products as a complete and systematic solution for epigenetics-related research and drug discovery. The company has developed a comprehensive portfolio of more than 400 proprietary products that are used all around the world by esteemed academia, leading pharmaceuticals, and cutting edge biotechnology companies. These unique products are specifically designed to make assays significantly more simple, fast, convenient and efficient than conventional methods. The company, particularly emphasizing speed and effectiveness in its technologies, continues to focus on epigenetic innovation and to extensively develop and enhance its product portfolio.

Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Companies' expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Companies' operations and conditions in the markets the Companies serve. The Companies do not undertake any obligation to update these forward-looking statements.

Sigma-Aldrich is a registered trademark of Sigma-Aldrich Biotechnology L.P. and Sigma-Aldrich Co.

'/>"/>

SOURCE Sigma-Aldrich Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Sigma-Aldrich Releases WTA2, a Transplex Whole Transcriptome Amplification Technology for Degraded RNA Samples
2. Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares.
3. Sigma-Aldrich Welcomes Memorial Sloan-Kettering Cancer Center to the RNAi Partnership Program
4. Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement
5. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in Peer-Reviewed Video Journal JoVE
6. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in PubMeds Peer-Reviewed Video Journal JoVE
7. Sigma-Aldrich to Present at the UBS 2008 Global Life Sciences Conference on September 24, 2008
8. Sigma-Aldrich Launches Breakthrough Genome-Editing Tools
9. Sigma-Aldrich Signs Exclusive Agreement With IsoSciences, LLC, to Distribute Isotopically Labeled Bioactive Compounds
10. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
11. Sigma-Aldrich (Nasdaq: SIAL) Reports 16.7% Gain in Q2 2008 Diluted EPS. Q2 2008 Sales Rise 14.4%. 2008 Diluted EPS Forecast Raised $.05 to $2.62-$2.72.